E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
In Denmark there is approximately 3600 new cases of Colorectal cancer every year. In Denmark about half of these patients will eventually develop metastatic disease. In Denmark it is suggested that 150 patients each year will be in such good performance to third line chemotherapy. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9 |
E.1.2 | Level | 1.0 |
E.1.2 | Classification code | 10010029 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
|
E.2.2 | Secondary objectives of the trial |
To evaluate and determine
· Time to progression after 1.day of start of therapy. · Overall survival from date start of therapy. · Safety and toxicity of the treatment · Influence of smoking on response to therapy, OS and TTP and other parameters investigated in the protocol. · Predictability of metabolic response as evaluated by a PET-scan two weeks after initiation of treatment (optional) on response to therapy, OS and TTP and other parameters investigated in the protocol. · The relation between potentially predictive and prognostic tumor biomarkers
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Patient with histological proven MCRC. 2. Patients must have measurable disease, according to RECIST criteria. 3. Irinotecan resistant disease i.e. progressive disease after at least 6 weeks of therapy with Irinotecan-containing therapy or within 3 months thereafter. 4. Age ≥18 years. 5. Performance status (WHO) of 0-2. 6. Patient must have a life expectancy of at least 3 months. 7. Adequate hematological function defined ANC ³1.5 x 109/l 1. Patient with histological proven MCRC. 2. Patients must have measurable disease, according to RECIST criteria. 3. Irinotecan resistant disease i.e. progressive disease after at least 6 weeks of therapy with Irinotecan-containing therapy or within 3 months thereafter. 4. Age ≥18 years. 5. Performance status (WHO) of 0-2. 6. Patient must have a life expectancy of at least 3 months. 7. Adequate hematological function defined ANC ³1.5 x 109/l and platelets ≥100 x 109/l . 8. Adequate liver function defined as Bilirubin ≤ 1,5 x UNL (upper normal limit) and/or ASAT/ALAT ≤ 5 x UNL. 9. All should have been exposed to Oxaliplatin-containing therapy. 10. Written informed consent must be obtained according to the local Ethics Committee requirements. platelets 100 x 109/l . 8. Adequate liver function defined as Bilirubin ≤ 1,5 x UNL (upper normal limit) and/or ASAT/ALAT ≤ 5 x UNL. 9. All should have been exposed to Oxaliplatin-containing therapy. 10. Written informed consent must be obtained according to the local Ethics Committee requirements.
|
|
E.4 | Principal exclusion criteria |
1. Previous or some other concomitant malignancy, with the exception of adequately treated basal cell skin cancer or in situ cervical cancer. 2. Inability to follow the treatment and evaluation schedule. 3. Any other condition or therapy which in the investigator’s opinion may pose a risk to the patient or interfere with the study objectives. 4. Pregnant or lactating women. In fertile women this is ensured by a negative pregnancy test or use of safe antikonception (as defined by the Danish medicines agency during the study period and at least 3 months thereafter. 5. Patients with active infections or other serious underlying medical condition, which would impair the ability of the patients to receive the protocol treatment. 6. Known hypersensitivity to any of the components of the treatment. 7. Legal incapacity. 8. Reduced liver function defined by bilirubin > 5 x UNL or ASAT/ALAT > 5xUNL
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study is finished when a number of 100 evaluable patients have completed the treatment according to the protocol. Evaluable patients are patients included with at least one objective response evaluation two months after initiation of therapy.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |